The world's first wiki where authorship really matters. Imagine a global collaborative knowledge base for original thoughts. Open access and freely available to everyone.
mememoir wiki meme memoir author authorship tracking technology evolutionary knowledge reputation system wiki2.0 global collaboration memes
 
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
 
 
 
 
 

Treatment of Parkinson's disease with lergotrile mesylate.

Lergotrile mesylate, an ergot alkaloid derivative and putative dopamine agonist, was effective in the majority of patients with Parkinson's disease who were showing signs of disease progression despite treatment with levodopa combined with a peripheral decarboxylase inhibitor (carbidopa). Among 20 patients completing a six-month trial, there was a significant (P less than .01) reduction in rigidity, tremor, bradykinesia, gait disturbance, and total score when lergotrile was added to levodopa plus carbidopa. Mean daily dose of lergotrile mesylate was 52 mg, and the mean daily dose of levodopa was reduced by 15%. Abnormal involuntary movements were decreased on addition of lergotrile and reduction in levodopa while mental changes and orthostatic hypotension were increased. Elevations in serum transaminase levels were noted in three patients. The ergot alkaloids promise to be an important new class of antiparkinsonian drugs.[1]

References

  1. Treatment of Parkinson's disease with lergotrile mesylate. Lieberman, A., Estey, E., Kupersmith, M., Gopinathan, G., Goldstein, M. JAMA (1977)
 

Editor

Links